First I will clarify that I am an ex-holder with a fairly negative view on this company. The announcement came across differently to me. First of all - the rights to a product is different to giving the 'IP outright' remembering that the IP is on the adapt process of treating the tissue. Making pericardium patches in general isn't such a big deal (with the exclusion of the 3D model).
The manufacturing costs + a built in margin will be applied for supplying LMAT. This will cover the COGS incurred. Not sure what the operational / 'corporate' costs incurred as a direct result of the operation in WA but my guess that most of the fat is in the executive/management and sales positions. The sales positions will disappear (recruitment, training, wages) but costs incurred for regulatory/legal, administrative, R&D will be there still...
It'll be interesting to see how this pans out from here on.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-141
-
- There are more pages in this discussion • 149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.70 |
Change
-0.300(1.58%) |
Mkt cap ! $359.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.62 | $180.3K | 9.596K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 475 | $18.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.91 | 100 | 1 |
View Market Depth
| Last trade - 14.41pm 20/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |